What Happened
- After the US Supreme Court struck down tariffs imposed under IEEPA on February 20, 2026, President Trump signed an executive order invoking Section 122 of the Trade Act of 1974 to impose a new 10% global tariff on all imports, citing "large and serious" US balance-of-payments deficits.
- This new 10% tariff replaced the previously negotiated bilateral tariff rates — including rates agreed with India under the interim trade framework — effectively applying the same rate to all countries.
- Within 24 hours, Trump raised the tariff from 10% to 15%, announcing it on Truth Social and characterising the Supreme Court ruling as "extraordinarily anti-American."
- Countries that had negotiated trade deals with the US, including India (18% interim rate), now face the flat 15% global tariff instead of their bilaterally agreed rates.
- Section 122 tariffs are temporary by law — they must expire in 150 days unless extended by Congress.
Static Topic Bridges
Section 122 of the Trade Act of 1974: Balance-of-Payments Tariffs
Section 122 of the Trade Act of 1974 grants the US President authority to impose temporary import surcharges of up to 15% or import quotas when the country faces "large and serious balance-of-payments deficits" or when there is a risk of significant dollar depreciation. Unlike the lengthy investigations required under Section 232 (national security) or Section 301 (unfair trade practices), Section 122 allows the President to act rapidly. However, such tariffs are strictly temporary — capped at 150 days — and require Congressional approval for any extension.
- Enacted as part of the Trade Act of 1974, modelled on Nixon's 1971 temporary 10% surcharge
- Historically linked to the Bretton Woods system's breakdown — intended for currency crisis scenarios
- Maximum surcharge: 15% on all imports, or selective quotas
- Duration: 150 days maximum without Congressional extension
- Expert criticism: The US currently runs a capital account surplus, making "balance-of-payments deficit" justification legally and economically contested
- Trump White House invoked this citing trade deficits as equivalent to balance-of-payments problems — a contested interpretation
Connection to this news: After losing the IEEPA legal battle, the Trump administration pivoted to Section 122 as a rapid-response alternative, sacrificing the bilateral deal framework in favour of a uniform global tariff — affecting India's 18% negotiated rate.
US Trade Policy Frameworks: IEEPA, Section 232, Section 301, and Section 122
US presidents have multiple legal tools to impose tariffs without Congress — each with different scope, duration, and legal requirements. IEEPA (struck down by Supreme Court in Feb 2026) required a national emergency declaration. Section 232 allows tariffs on national security grounds after a Commerce Department investigation. Section 301 targets unfair foreign trade practices after a USTR investigation. Section 122 is the fastest tool — no investigation required — but the most temporary. The legal patchwork creates uncertainty for trading partners about which authority governs at any given time.
- Section 232: Used for steel (25%) and aluminium (10%) tariffs — upheld in courts; no expiry
- Section 301: Used for China tariffs ($300B+ in goods) — requires USTR review, no fixed expiry
- IEEPA: Struck down Feb 20, 2026 — cannot be used for broad tariffs going forward
- Section 122: 10-15% cap, 150-day limit, no investigation needed
- Administration indicated it will also rely on existing Section 232/301 tariffs that survived the Supreme Court ruling
Connection to this news: The shift from IEEPA to Section 122 is a legal workaround with significant trade-offs — India and other countries with bilateral deals now face a less favourable, non-differentiated tariff environment.
India's Export Competitiveness and Tariff Exposure
India's export basket to the US is diverse, spanning pharmaceuticals, software services, textiles and garments, gems and jewellery, engineering goods, and chemicals. A higher tariff environment directly affects the competitiveness of Indian goods vis-a-vis competitors like Vietnam and Mexico. India's pharmaceutical sector, which supplies nearly 40% of US generic drug requirements, has typically enjoyed zero or low tariffs. A blanket 15% tariff impacts both price-sensitive goods and those with fewer substitutes.
- India's merchandise exports to US (FY 2024-25): approximately $77 billion
- Key export categories: pharmaceuticals (~$8B), engineering goods, textiles, gems & jewellery, chemicals
- India's pharmaceuticals: 40% of US generic drug requirements — previously zero/low tariff
- Competing exporters: Vietnam (also faces global tariff), Mexico and Canada (under USMCA — exempted from Section 122 tariffs)
- Net impact: India moves from 26% IEEPA → 18% interim deal → 15% Section 122 — still an improvement over original IEEPA rate
Connection to this news: While the 15% global tariff is lower than the 26% IEEPA rate, it replaces the more favourable 18% interim bilateral agreement, creating a mixed outcome for Indian exporters.
Key Facts & Data
- Section 122 tariff signed by Trump: February 20, 2026 (hours after Supreme Court ruling)
- Initial rate: 10%; raised to 15% within 24 hours (February 21, 2026)
- Legal basis: Section 122, Trade Act of 1974 — balance-of-payments authority
- Maximum legal rate under Section 122: 15%
- Expiry: 150 days from imposition unless Congress extends
- India's previous tariff trajectory: 26% (IEEPA) → 18% (interim deal) → 15% (Section 122)
- USMCA countries (Mexico, Canada) may be exempt from Section 122 global tariff
- US trade deficit (goods) in 2024: approximately $1.2 trillion — administration's stated justification
- Countries impacted: all trading partners that had bilateral deals with the US replaced by flat 15%